Unit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico "Dr. Eduardo Liceaga", 06726 Mexico City, Mexico.
Departamento de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510 México, DF, Mexico.
J Diabetes Res. 2018 Feb 21;2018:7209872. doi: 10.1155/2018/7209872. eCollection 2018.
Experimental evidence in mice suggests a role for interleukin- (IL-) 13 in insulin resistance and low-grade systemic inflammation. However, IL-13 serum levels have not been assessed in subjects with insulin resistance, and associations of IL-13 with parameters of low-grade systemic inflammation are still unknown. Our main goal was to examine the systemic levels of IL-13 in patients with insulin resistance, while also studying the relationship of IL-13 with anthropometric, metabolic, and low-grade systemic inflammatory markers. Ninety-two participants were included in the study and divided into insulin-resistant patients and noninsulin-resistant controls. Blood levels of IL-13, glucose, insulin, triglycerides, cholesterol, tumor necrosis factor-alpha (TNF-), IL-10, proinflammatory (Mon-CD11cCD206), and anti-inflammatory (Mon-CD11cCD206) monocytes, as well as anthropometric parameters, were measured in all volunteers. Insulin-resistant patients showed 2.5-fold higher serum levels of IL-13 than controls ( < 0.0001) and significantly increased values of TNF- and Mon-CD11cCD206, with concomitant reductions in IL-10 and Mon-CD11cCD206. Increased IL-13 was extraordinarily well associated with hyperglycemia ( = 0.7362) and hypertriglyceridemia ( = 0.7632) but unexpectedly exhibited no significant correlations with TNF- ( = 0.2907), IL-10 ( = -0.3882), Mon-CD11cCD206 ( = 0.2745) or Mon-CD11cCD206 ( = -0.3237). This study demonstrates that IL-13 serum levels are elevated in patients with insulin resistance without showing correlation with parameters of low-grade systemic inflammation.
实验证据表明，白细胞介素-13（IL-13）在胰岛素抵抗和低度全身炎症中起作用。然而，尚未在胰岛素抵抗患者中评估 IL-13 的血清水平，并且 IL-13 与低度全身炎症参数的关系仍不清楚。我们的主要目标是检查胰岛素抵抗患者的全身 IL-13 水平，同时研究 IL-13 与人体测量学、代谢和低度全身炎症标志物的关系。本研究共纳入 92 名参与者，分为胰岛素抵抗患者和非胰岛素抵抗对照组。所有志愿者均测量了 IL-13、血糖、胰岛素、甘油三酯、胆固醇、肿瘤坏死因子-α（TNF-）、IL-10、促炎（Mon-CD11cCD206）和抗炎（Mon-CD11cCD206）单核细胞以及人体测量参数的血清水平。与对照组相比，胰岛素抵抗患者的血清 IL-13 水平高出 2.5 倍（<0.0001），TNF-和 Mon-CD11cCD206 显著升高，同时 IL-10 和 Mon-CD11cCD206 降低。IL-13 的增加与高血糖（=0.7362）和高三酰甘油血症（=0.7632）呈极好的相关性，但与 TNF-（=0.2907）、IL-10（=-0.3882）、Mon-CD11cCD206（=0.2745）或 Mon-CD11cCD206（=-0.3237）均无显著相关性。这项研究表明，胰岛素抵抗患者的血清 IL-13 水平升高，但与低度全身炎症参数无相关性。
